NLS Pharmaceutics ( (NLSP) ) just unveiled an update.
On January 30, 2025, NLS Pharmaceutics Ltd. amended its merger agreement with Kadimastem Ltd. and NLS Pharmaceutics (Israel) Ltd., extending the termination date to April 30, 2025. This extension aims to facilitate the completion of the merger process, with provisions in place for shareholders exceeding ownership limitations to receive pre-funded warrants. The companies remain committed to fulfilling all regulatory requirements, indicating a significant step in their collaborative efforts to finalize the merger.
More about NLS Pharmaceutics
NLS Pharmaceutics Ltd. is a pharmaceutical company based in Zurich, Switzerland, primarily engaged in the development of therapeutics. It focuses on innovative treatments for neurological and psychiatric disorders. The company is involved in a merger with Kadimastem Ltd., an Israeli company, indicating a strategic move to enhance its market presence and capabilities.
YTD Price Performance: -9.17%
Average Trading Volume: 1,202,706
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $4.9M
For detailed information about NLSP stock, go to TipRanks’ Stock Analysis page.